Clinical trials: Subjects With Type 2 Diabetes Mellitus.
Type 2 Diabetes Mellitus
Safety and Efficacy of Bexagliflozin as Monotherapy in Patients With Type 2 Diabetes
The purpose of this study is to investigate the effect of bexagliflozin in lowering hemoglobin A1c (HbA1c) levels in patients with type 2 diabetes mellitus (T2DM).
- Trial name
- NCT02715258
- Testing
- Bexagliflozin
- Where
- 23 sites in United States, Canada
- Volunteers
- 210 people
- Sponsor
- Theracos
Diabetes
A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GZR4 in Subjects With Type 2 Diabetes
This trial is conducted in China. The aim of the trial is to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of mutiple-dose GZR4 in subjects with type 2 diabetes
- Trial name
- NCT06553248
- Testing
- GZR4, Insulin Degludec
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Gan and Lee Pharmaceuticals, USA
Type 2 Diabetes
The DDI Study of SP2086 and Simvastatin
The purpose of the study is to investigate the potential interaction between multiple oral doses of SP2086 and a single oral dose of Simvastatin in healthy adult volunteers.
- Trial name
- NCT02817243
- Testing
- SP2086, Simvastatin
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Diabetes, Diabetes Mellitus, Type 2
Effect of Renal Impairment on the Pharmacokinetics of NN9535
This trial is conducted in the United States of America (USA). The aim of this clinical trial is to investigate how different degrees of renal impairment (mild, moderate, severe and end-stage renal disease) affect the…
- Conditions
- Diabetes, Diabetes Mellitus, Type 2, Renal Impairment
- Trial name
- NCT00833716
- Testing
- semaglutide
- Where
- 3 sites in United States
- Volunteers
- 62 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Diabetic Nephropathy
Phase 1 Study of FG-3019 in Subjects With Type 1 or Type 2 Diabetes Mellitus and Diabetic Nephropathy
The purpose of this study is to evaluate the safety and tolerability of two dosing regimens of FG-3019 administered over 12 weeks in patients with diabetic nephropathy and proteinuria on background angiotensin converting enzyme…
- Trial name
- NCT00754143
- Testing
- FG-3019
- Where
- 18 sites in United States
- Volunteers
- 38 people
- Sponsor
- Kyntra Bio
Type 2 Diabetes Mellitus
Study of MEDI0382 in Combination With Dapagliflozin and Metformin in Overweight/Obese Participants With Type 2 Diabetes
A Phase 2 study Comparing the effects on glucose control of MEDI0382 in combination with Dapagliflozin and Metformin compared to placebo in combination with Dapagliflozin and Metformin in overweight/obese participants with Type 2…
- Trial name
- NCT03444584
- Testing
- MEDI0382, Dapaglifozin, Metformin
- Where
- 8 sites in Germany, Hungary and 1 more
- Volunteers
- 49 people
- Sponsor
- MedImmune LLC
Diabetic Nephropathy, Diabetic Kidney Disease
Pyridorin in Diabetic Nephropathy
The purpose of this study is to evaluate the safety and efficacy of oral Pyridorin 300 mg BID in reducing the rate of progression of nephropathy due to type 2 diabetes mellitus.
- Trial name
- PIONEER (NCT02156843)
- Testing
- Pyridorin
- Where
- 137 sites in United States, Australia and 10 more
- Volunteers
- 328 people
- Sponsor
- NephroGenex, Inc.
Diabetes
Chinese Multiple Dose Escalation (MDE) High Dose Study
A Phase 1 Randomized, Double-blinded, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Cotadutide in Overweight/Obese Subjects with Chinese ancestry with Type 2 Diabetes Mellitus
- Trial name
- COTA China PK (NCT05437848)
- Testing
- Experimental: Cotadutide
- Where
- 2 sites in China
- Volunteers
- 16 people
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus, Telomere Shortening
Efficacy of Pythagorean Self-Awareness for Aging Biomarkers Improvement, in T2D Patients and Healthy Individuals.
The present study explored the effects of the implementation of the Pythagorean Self Awareness Intervention (PSAI) on the dynamics of stress-related aging factors of immune cells in healthy volunteers and a cohort patients with…
- Trial name
- NCT04763525
- Testing
- Pythagorean Self-Awareness Intervention(PSAI)
- Where
- Greece
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- National and Kapodistrian University of Athens
Type 2 Diabetes, Overweight
Effect of Liraglutide on Epicardial Fat in Subjects With Type 2 Diabetes
The purpose of this research study is to learn about the effect of Liraglutide, (Victoza®), on the fat surrounding the heart.Excessive amount of the fat around the heart is common in people with type 2 diabetes and can be…
- Conditions
- Type 2 Diabetes, Overweight, Obesity
- Trial name
- NCT02014740
- Testing
- Liraglutide, Metformin
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- University of Miami
Diabetes, Diabetes Mellitus, Type 1
Efficacy and Safety of Insulin Aspart in Subjects With Type 1 or Type 2 Diabetes
This trial is conducted in Asia. The aim of this trial is to compare the efficacy of postprandial plasma glucose of two treatment regimens in Chinese subjects.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT00593255
- Testing
- soluble human insulin, insulin aspart, insulin NPH
- Where
- 5 sites in China
- Volunteers
- 220 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
Effect of Liraglutide on the Beta-cell Responsiveness in Subjects With Type 2 Diabetes Compared to a Healthy Control Group
This trial is conducted in the United States of America (USA). The aim of this trial is to assess the effect of NNC 90-1170 on beta-cell responsiveness to increasing blood glucose concentrations in subjects with type 2 diabetes.
- Trial name
- NCT01511185
- Testing
- liraglutide
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
A 6-Week Study Of PF-05175157 In Type 2 Diabetes Mellitus
This study is designed to assess the safety, tolerability and pharmacodynamics of 6 weeks of oral doses of PF-05175157 provided as monotherapy in subjects with type 2 diabetes mellitus.
- Trial name
- NCT01792635
- Testing
- PF-05175157
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Pfizer
Diabetes Mellitus, Type 2
Gan & Lee Insulin Glargine Target Type (2) Evaluating Research
Primary Objective: To evaluate equivalence of Gan \& Lee Insulin Glargine Injection and Lantus® in terms of immunogenicity Secondary Objective: Immunogenicity: To evaluate the percentage of subjects with negative anti-insulin…
- Trial name
- GLITTER 2 (NCT03371108)
- Testing
- Gan & Lee Insulin Glargine Injection, Lantus®
- Where
- 57 sites in United States
- Volunteers
- 567 people
- Sponsor
- Gan and Lee Pharmaceuticals, USA
Diabetes Mellitus Type 1
A Double-blinded, Randomised, Two -Period Crossover Euglycemic Clamp Trial Investigating the Pharmacokinetics, Glucodynamics and Safety of BioChaperone Insulin Lispro and Insulin Lispro (Humalog®) in Subjects With Type 1 Diabetes
The addition of Biochaperone to insulin lispro may accelerate the onset and shorten the duration of action of insulin lispro due to a facilitation of the absorption of the insulin after subcutaneous injection.
- Trial name
- NCT02029924
- Testing
- BioChaperone insulin lispro, Humalog®
- Where
- Germany
- Volunteers
- 37 people
- Sponsor
- Adocia
Type 2 Diabetes
A Phase 1/2a Study of the 2S,4R Enantiomer of Ketoconazole in Subjects With Type 2 Diabetes Mellitus
The study is designed to test the safety, tolerability of a newly developed form of ketoconazole (DIO-902) for the treatment of elevated blood sugars in type 2 diabetes.
- Trial name
- NCT00302224
- Testing
- 2S, 4R Ketoconazole (DIO-902)
- Where
- 5 sites in United States
- Volunteers
- 50 people
- Sponsor
- DiObex
Diabetes Mellitus, Type 2
A Study of LY2409021 in Participants With Type 2 Diabetes Mellitus
The intent of this study is to assess the safety of LY2409021 in participants with Type 2 diabetes mellitus taking metformin and sulfonylurea as prescribed by their personal physician.
- Trial name
- NCT02111096
- Testing
- LY2409021, Sitagliptin, Metformin
- Where
- 33 sites in United States, Greece and 2 more
- Volunteers
- 174 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes Mellitus
A Trial to Compare Post Prandial Blood Glucose Control of BioChaperone® Combo With Humalog® Mix25 and With Simultaneous Injections of Humalog® and Lantus® in Subjects With Type 2 Diabetes
This is a two-centre, randomised, double-blind, double-dummy, 3-treatment, 3-period cross-over study using a standardised solid meal test in subjects with type 2 diabetes to investigate postprandial glucose control of…
- Trial name
- NCT02915250
- Testing
- BioChaperone® Combo, Humalog® Mix25, Humalog®
- Where
- 2 sites in Germany
- Volunteers
- 36 people
- Sponsor
- Adocia
Type 2 Diabetes Mellitus
An Open-label, Multi-center, International, Three-year, Safety and Tolerability 'Follow on' Trial
Safety Follow-Up Trial to PDC-INS-0008 and MKC-TI-005
- Trial name
- NCT00754624
- Testing
- Technosphere® Insulin Inhalation Powder and MedTone™ Inhaler
- Where
- 40 sites in United States, Bulgaria and 2 more
- Volunteers
- 229 people
- Sponsor
- Mannkind Corporation
Diabetes, Diabetes Mellitus, Type 2
Comparison of Insulin Detemir and NPH Insulin Given Once Daily in Ageing Subjects With Type 2 Diabetes
This trial is conducted in Europe. The aim of the trial is to compare insulin detemir once daily to NPH insulin once daily as measured by blood sugar control in ageing subjects with type 2 diabetes naive to previous insulin…
- Trial name
- 3L (NCT00506662)
- Testing
- insulin detemir, insulin NPH
- Where
- 2 sites in France, United Kingdom
- Volunteers
- 86 people
- Sponsor
- Novo Nordisk A/S
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.